Introduction：Basic information about CAS 722533-56-4|Elacestrant, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Elacestrant |
|---|
| CAS Number | 722533-56-4 | Molecular Weight | 458.635 |
|---|
| Density | 1.1±0.1 g/cm3 | Boiling Point | 609.5±55.0 °C at 760 mmHg |
|---|
| Molecular Formula | C30H38N2O2 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 322.4±31.5 °C |
|---|
Names
| Name | Elacestrant |
|---|
| Synonym | More Synonyms |
|---|
Elacestrant BiologicalActivity
| Description | Elacestrant (RAD1901) is a selective and orally available estrogen receptor (ER) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively. |
|---|
| Related Catalog | Signaling Pathways >>Others >>Estrogen Receptor/ERRResearch Areas >>Cancer |
|---|
| Target | IC50: 48 nM (ERα), 870 nM (ERβ)[1] |
|---|
| In Vitro | RAD1901 selectively binds to and degrades the ER and is a potent antagonist of ER-positive breast cancer cell proliferation. RAD1901 treatment exhibits dose-dependent inhibition of ERα expression, with an EC50 of 0.6 nM. Treatment of ER-positive MCF-7 cells with E2 results in a potent and dose-dependent increase in proliferation, with an EC50 of 4 pM. Treatment of cells with RAD1901 in the presence of 10 pM E2 resultsin a dose-dependent decrease in proliferation, with an IC50 value of 4.2 nM[1]. |
|---|
| In Vivo | RAD1901 produces a robust and profound inhibition of tumor growth in MCF-7 xenograft models. RAD1901-treated animals survived longer than those treated with either control or fulvestrant. RAD1901 preserves ovariectomy-induced bone loss and preventes the uterotropic effects of E2[1]. |
|---|
| Kinase Assay | RAD1901 is serially diluted in ES2 screening buffer to concentrations ranging from 10 to 10-6 μM. Aliquots (25 μL) of each dilution are added to a black 384-well microtiter plate, in triplicate. The ER–Fluormone complex is prepared as directed, with 2 nM Fluormone ES2 and 30 nM ER. A 25 μL aliquot of this preparation is added to each reaction well. The plates are sealed and incubated in the dark at room temperature for 4 h. Polarization values for each well are measured and plotted against the concentration of the test compound. The IC50 is determined from at least three independent experiments, with E2 serving as a positive control[1]. |
|---|
| Cell Assay | For proliferation assays, MCF-7 cells are treated with 2% charcoal-stripped FBS–MEM containing 10 pM E2 with either RAD1901 or additional E2 at concentrations ranging from 10-9 to 1 M. The medium is removed after 48 h of incubation and the cells are lysed by adding 100 μl of CellTiter Glo. The plates are gently mixed on a plate shaker for 10 min before the luminescent signal is measured on a luminometer. The EC50 and IC50of the test compound are then defined[1]. |
|---|
| Animal Admin | Mice: RAD1901 is stored as a dry powder, formulated for use as a homogenous suspension in 0.5% (w/v) methylcellulose in deionized water. Fourteen days after tumor cell implantation, the mice are randomized into nine groups of 15 animals each and treated with vehicle, tamoxifen (1 mg/animal every other day), fulvestrant (0.5 mg/animal daily), or RAD1901 (0.3, 1, 3, 10, 30, 60, 90, and 120 mg/kg daily). Tumor volumes are evaluated twice per week[1]. |
|---|
| References | [1]. Garner F, et al. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26(9):948-56. |
|---|
Chemical & Physical Properties
| Density | 1.1±0.1 g/cm3 |
|---|
| Boiling Point | 609.5±55.0 °C at 760 mmHg |
|---|
| Molecular Formula | C30H38N2O2 |
|---|
| Molecular Weight | 458.635 |
|---|
| Flash Point | 322.4±31.5 °C |
|---|
| Exact Mass | 458.293335 |
|---|
| LogP | 7.07 |
|---|
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
|---|
| Index of Refraction | 1.604 |
|---|
| Storage condition | 2-8℃ |
|---|
Synonyms
| elacestrant |
| 2-Naphthalenol, 6-[2-[ethyl[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydro-, (6R)- |
| FM6A2627A8 |
| UNII:FM6A2627A8 |
| (6R)-6-[2-(Ethyl{4-[2-(ethylamino)ethyl]benzyl}amino)-4-methoxyphenyl]-5,6,7,8-tetrahydro-2-naphthalenol |
| 10247 |
